Preventing kidney and heart damage in type 2 diabetes
Treatments studied
Part of Heart & circulation, Hormones & metabolism, Kidney & urinary clinical trials.
This study tests whether diabetes medicines can help prevent worsening heart and kidney problems in people with type 2 diabetes. You’ll be assigned by chance to one of these medicine types, and your other care will be adjusted for safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes (not type 1 or another rare type).
- Your diabetes lab test (HbA1c) was at least 6% within the last 12 months.
- You’re in a “secondary prevention” group (about 70% of participants) with age 40–80 and known blood-vessel disease from the heart, brain, or legs; or you fit the smaller “primary prevention” group (age 60–80 plus high-risk features).
- Your kidney function is not too low (eGFR must be 45 or higher for enrollment).
- You can take part in the random assignment of medication type (SGLT2 tablet/therapy and/or GLP-1 injection/therapy) through your usual pharmacy plan.
- You agree to use your medical record data and sign a release to get records from other doctors if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 trial studies an approach to help prevent heart problems in adults with type 2 diabetes who are at higher heart risk. It may help reduce future cardiovascular events by testing medications for safety and benefit in this group.
This study compares different diabetes medicines to see which works best for people with type 2 diabetes who also have heart or blood vessel risks. It aims to find better treatment to protect your heart and kidneys.
This trial studies how diabetes medicines (GLP-1 and SGLT2, alone or together) affect the heart in people with type 2 diabetes who are at higher cardiovascular risk and have heart failure with preserved pumping function. It may help find safer or more effective ways to reduce heart problems.
This study looks at whether two types of diabetes medications—SGLT2 inhibitors and GLP-1 receptor agonists—help protect the heart in people with type 2 diabetes. It involves a first group that reviews past medical records, and a second group that will be monitored for 6 months after starting an SGLT2 inhibitor to see how their heart function changes.
This trial looks at whether a medicine called an SGLT2 inhibitor (a type of diabetes drug) can help protect the kidneys and heart in people with chronic kidney disease or type 2 diabetes. If you have either condition, you might be able to join.
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
Hear when a new Type2diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.